News

MOST study shows high rates of disease progression in low/intermediate-risk myelofibrosis over 4 years, with the rate increasing over time. This offers valuable insight for a patient group with limited prior data.

Tarah Ballinger, MD, discusses what she considers to be the biggest developments from the 2024 ASCO Annual Meeting.

Paolo Ghia, MD, PhD, discusses background of the phase 2 CAPTIVATE trial.

The phase 3 SIERRA study revealed that only Iomab-B recipients achieved the primary end point of durable complete remission.

Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

Finly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.

Chakra Chaulagain, MD, discusses findings from a comprehensive examination of National Cancer Database data from 2004 to 2020 regarding the utilization of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

The FDA granted approval to repotrectinib for the treatment of metastatic or locally advanced solid tumors with an NTRK gene fusion.

In an interview with Targeted Oncology, Sarah Sammons, MD, discussed an analysis of the DESTINY-Breast03 trial, highlighting the need for further research on trastuzumab deruxtecan in other breast cancer subtypes and solid tumors with brain metastases.

Francis P. Worden, MD, provides a brief overview of the approval of selpercatinib and what it means for patients with RET fusion-positive thyroid cancer.

Findings from a phase 1 trial presented at ASCO showed that axicabtagene ciloleucel was safe with clinical activity seen among patients with relapsed/refractory primary and secondary central nervous system lymphoma.

Patients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.

Anita Boyapati, PhD, discussed her research on the link between soluble BCMA and both disease burden and response to BCMA-targeted therapies in this patient population.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

A self-taught AI tool that accurately diagnoses adenocarcinoma and predicts cancer recurrence has been developed and has shown to outperform traditional methods.

More than half of all patients do not remember their physicians’ recommendations and treatments unless prompted.

Cesar Augusto Perez, MD, discusses the efficacy data reported in a phase 2 study of petosemtamab plus pembrolizumab for the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma.

Sawsan Rashdan, MD, discusses the background, findings, and next steps of a phase 2 study evaluating treatment with osimertinib and consolidative SABR for the treatment of EGFR-mutated NSCLC.

A cyberattack on Change Healthcare disrupted patient scheduling, billing, and potentially exposed patient data. It caused financial strain on medical practices and took weeks to recover from.

SL-172154 is being studied in a phase 1a/1b study in acute myeloid leukemia and higher-risk myelodysplastic syndrome, as well as other phase 1 studies in platinum-resistant ovarian cancer.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the importance of considering a drug's overall value beyond just its initial price per mg.

Aditya Bardia, MD, MPH, discusses results of a biomarker analysis of the TROPiCS-02 study of sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer presented at ASCO 2024.

An investigational new drug application for lomonitinib has been cleared by the FDA for FLT3-mutated relapsed/refractory AML treatment, and a phase 1 trial evaluating the agent will begin in the US.

William Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.

David Samuel Dicapua Siegel, MD, shared his perspectives on promising areas of research that could advance the care of patients with myeloma.

Premal Thaker, MD, discussed the ACCC Ovarian Quality of Care Project aiming to bridge the gap to improve ovarian cancer care for patients in the US.